International Journal of PharmaO2
Journal Home Page: http://www.ijpo.in/
(IJPO: A Peer-reviewed Bi-monthly online journal)

Review

Congo Hemorrhagic Fever: Mutated Old Flu New Threat to Mankind

Gopavaram Sumanth*, Hindustan Abdul Ahad, Chinthaginjala Haranath, Palagiri Nitish Kumar Reddy, Pani Sai Raghava, DR. Ksheerasagare Tarun

Department of Industrial Pharmacy, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) -Autonomous, Ananthapuramu – 515721, Andhra Pradesh, India.

ARTICLE INFO

Article history:
Received: 31/10/2020;
Revised: N.A.;
Accepted: 03/11/2020;
Available online: 04/11/2020.

Key Words:
CCHF,
Pathogenesis,
Transmission,
Control.

Please cite this article as: Sumanth G., *et al.*, (2020). Congo Hemorrhagic Fever: Mutated Old Flu New Threat to Mankind. *International Journal of PharmaO2*, 2(6), 0380-0385.

ABSTRACT

In the extreme types of fatality hemorrhagic fever transmitted through bites of contaminated ticks or body fluids of contaminated individuals is Crimean-Congo hemorrhagic fever (CCHF). The absence of powerful examinations and the endemic capability of the sickness represents a huge general wellbeing danger. As the infection can prompt scourges, has an incredible case casualty proportion (10-40 percent), possibly brings about emergency clinic and wellbeing office flare-ups, and is trying to hinder and treat, CCHF flare-ups represent a danger to general wellbeing administrations. For anticipation and restorative advances, early location utilizing ELISA (compound connected immunoassay) and atomic instruments, for example, RT-PCR (continuous opposite record polymerase chain response) is useful. Notwithstanding, while no antiviral drug is presently existing for CCHF, immunotherapy and ribavirin has been built up to be effective during irregular infection episodes. This audit gives the pathogenesis, the study of disease transmission, signs and indications, control, and avoidance of CCHF.

*Corresponding author: Mr. Gopavaram Sumanth, Department of Industrial Pharmacy, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) -Autonomous, Ananthapuramu – 515721, Andhra Pradesh, India. Contact:+91-6309193848, e-mail: sumanth925@gmail.com

Introduction

Broad ecchymosis, dying, and hepatic brokenness are viewed as Crimean-Congo hemorrhagic fever (CCHF), an intense viral illness in people, and are aligned with a 30% case-passing proportion (Whitehouse CA, 2004). It is delivered by the infection CCHF (Nairovirus class, Bunyaviridae family) (Karti SS et al, 2004). Inside the spreading assortment of ticks of the sort Hyalomma, CCHF is a viral zoonosis that is sent by ticks that happens by and large in Africa, eastern Europe, and Asia (Nasirian H, 2020). In the Crimean Peninsula, a sickness called CHF was first seen in 1944, and the connective operator secluded in 1967 was discovered to be like the Congo infection detached from a febrile kid in the Belgian Congo in 1956, the terms Crimean and Congo are hence

utilized related (Papa A *et al*., 2002). CCHF is a zoonotic ailment spread by ticks too little and immense vertebrates and to flying creatures. Even though the infection has been isolated from numerous genera and class of ixodida ticks, ticks of the variety Hyalomma will in general be the key bunch of vectors complex in CCHF infection transmission (Estrada-Pena A *et al*, 2012). By supporting on contaminated minuscule vertebrates, youthful ticks gain the infection. At the point when contaminated, they endure tainted all through their development and spread the disease to enormous creatures, including domesticated animals, when they are developed. Transovarian spread has been seen as well. Hyalomma ticks are common in all of Europe, Asia, the middle East, East Asia, and Africa, and all of these regions have been established to have CCHF virus evidence. The virus is spread to humans through infected tick bites, straight contact with viremic animal blood or diseased tissue, and straight contact with the infected person's blood or secretions. For around 1week later infection, animals are viremic but have an only mild fever, which sometimes goes unnoticed. Usually, the gestation period is 5-6 days following blood contact. There have been many nosocomial CCHF eruptions mentioned, as with extra haemorrhagic fever, such as Ebola fever. In amplifying transmission, anabsence of services and sanitation in medical facilities plays a part (Jarhling PB *et al*,2007).Hospitalized patients frequently bleed and are extremely viremic; these patients may infect appearing medical workers and other patients who come into interaction with their blood or vomit in congested hospitals where there are no isolation steps taken.

History of CCHF

The first proof of CCHF in the 12th century, where the diagnosis of Tajikistan's hemorrhagic syndrome and the diagnosis of the disease-causing arthropod seem to be similar to modern-day CCHF. During World War II (1944-45), CCHF was first recognized among Soviet Union military personnel in Crimea and it called Crimea hemorrhagic fever (Appannanavar SB and Mishra B., 2011). The virus was separated using intracerebral vaccination of nursling mice from the patient blood and tissues. The virus accountable for hemorrhagic fever in Crimea was subsequently exposed to be indistinguishable from the Congo virus that produced febrile disease in the Belgian Congo.

Clinical findings and Pathogenesis

Popular laboratory findings indicate elevated levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatine kinase (CK),lactate dehydrogenase (LDH),extended prothrombin time (PT), activated partial thromboplastin time (APTT) for leukopenia and thrombocytopenia in CCHF patients (Tanir G *et al*, 2009). A complex association among the virus and human cells is probable to result in CCHF pathogenesis. Kupffer cells, endothelial hepatic cells, and hepatocytes are supposedly major CCHF targets. Hepatocyte necrosis mains to a spike in liver enzymes. New research on CCHF indicates that for patients with serious disease, the AST / ALT ratio is higher than for those with the moderate disease (Gunaydin N *et al*., 2010).Also, the enlarged expression of myeloperoxidase in leukocytes contributes to increased lysis of leukocytes. Leukopenia can therefore be related to lysis in CCHF patients. The coagulation cataract can be triggered by an endothelial injury, which ultimately leads to diminished platelet numbers or function. Coagulation activation can also lead to the growth of dispersed intravascular coagulation and organs failure. The vasculature leakage seen in CCHF occurs owing to direct virus infection or damage produced by released cytokines. The latest studies indicate higher interleukin (IL)-1, IL-6, and tumour necrosis factor (TNF)-alcohol levels in CCHF patients. Besides, in fatal cases, IL-6 and TNF-alpha levels are higher relative to nonfatal cases. Endothelial damage might lead to hemostatic failure and a skin rash that is characteristic (Tasdelen Fisgin N *et al*., 2008).

Transmission

The geographical dispersal of cases of CCHFV correlates most closely to the supply of members of the Hyalomma genus, suggesting their

principal position as vectors. Numerous tick species, including 2 Argaisdaeand 28 Ixodea spp, were isolated from CCHFV. In the geographical feast of the virus, argasids don't play a significant role because CCHFV fails to propagate argasid tick class in adults and nymphs (Yildirmak T *et al*., 2016). Ticks contain 4 stages of life: foetus, larvae, adult, and nymph. Larvae hatch from the eggs, climb plants, and bind to passing animals; because of heat and carbon dioxide concentrations, attraction to host occurs. Some species of genera Hyalomma, Dermacentor, and Rhipicephalus are capable of transmitting CCHFV after eating on a viremic host (i.e., transferring the virus from larva to nymph to adult). For some species in these genera, transovarial transmission occurs in CCHFV. Among certain vector species, a venereal transmission has shown, which may prime to keeping the circulation of the virus in nature. Ticks can also be contaminated by co-feeding on uninfected hosts with infected ticks (Halstead SB et al, 2001).The virus is contaminated to humans via tick bites or direct interaction with contaminated animal blood (farmers, slaughter workers, veterinarians, etc).Furthermore, infection from individual to individual may occur due to contact with the mucous membranes, skin, or body fluids of diseased patients. The virus can also be transmitted from humans to humans, mainly in the hospital environment. Since high temperatures can hasten the Hyalomma cycle, particularly in summer and spring, by swapping on its inter stage growth and host-seeking activity, the climate can cause an increased abundance of ticks (Tsai TF, 1987).

Epidemiology

The tick-borne viruses that mark human health, the geographical series of CCHF viruses is the broadest, and the second greatest widespread of all medically significant arboviruses after the dengue virus. Almost 140 outbreaks including more than 5,000 cases had been recorded since 1967 in entire the world (Hoogstraal H, 1979).A total of 52 countries are classified as potentially endemic areas, with more cases registered annually. There is also broad distribution in the spreading of Hyalomma spp., the main tick vector. In the initial years after the virus was first identified in 1967, the popular cases were reported from the former Soviet Union (Crimea, Astrakhan, Rostov, Uzbekistan, Kazakhstan, Tajikistan) and Bulgaria. In the years that followed, outbreaks were recorded from parts of Africa, such as the Democratic Republic of Congo, Uganda, and Mauritania. Middle Eastern countries such asSaudi Arabia and Iraq have also registered a huge number of incidents (Bente DA *et al*., 2013). Most cases from Turkey, Bulgaria, Pakistan, Iran, and even India were noted in the earlier decade. More number of these epidemics is got in the community; interaction with tick-infested farm animals is also noted. However, in some epidemics, nosocomial dissemination has been conversant were the key mode of spreading has been contacting with bloodand fluids from patients (Izadi S *et al*., 2004).

Signs and Symptoms

The duration of the growth cycle rests on the method of virus acquisition. The growth period is normally three days, andextreme of nine days, and subsequent infection through a tick bite. The duration of incubation subsequent contact with contaminated tissues (or) blood is typically six days, andan extreme of 13 days recorded (Swanepoel R *et al*., 1989).With fever, myalgia (muscle hurt), tipsiness, neck agony and firmness, back torment, cerebral pain, sore eyes, and photophobia (affectability to light), the wince of manifestations is sudden. Early on, vomiting, nausea, stomach pain, diarrhoea, sore throat can occur, followed by shrill swings of mood and confusion. Sleepiness and depression may replace the anxiety next 2-4 days, and pain in the abdomen may be localized to the upper right quadrant with noticeable hepatomegaly (liver enlargement). Other clinical symptoms include lymphadenopathy (widened lymph nodes), tachycardia (rapid heart rate), and petechial rash (skin bleeding rash) on the surfaces of the inner mucosa, like the mouth and neck, and the eyes (Mardani M *et al*., 2003). The petechiae, and further hemorrhagic phenomena, can yield to higher rashes called ecchymoses.There is generally a sign of hepatitis

after completion ofthe fifth day of illness, mainly ill patients may show rapid kidney degradation and pulmonary failure. With death happening in the second week, the CCHF mortality rate is around 30%. Improvement generally starts onthe tenth day after the beginning of illness in patients who recover (Ozkurt Z *et al*., 2006).

Diagnosis

Several separate laboratory tests can diagnose CCHF virus infection(Schwarz TF et al, 1996; Vanhomwegan J et al, 2012):

- Enzyme-linked immunosorbent (ELISA) assay;
- Identificationof antigens;
- Neutralizationof serum;
- Assay of reverse transcriptase-polymerase chain response (RT-PCR); and
- Isolation of viruses by cell culture.

There are normally no detectable antibody responsein patients with fatal disease, along with patients in the first few days of illness, and so diagnosis in these individuals is accomplished by virus or RNA recognition in tissue or blood samples. Tests on patient samples are of extreme biohazard concern and should be done only under optimum conditions of biological containment. Though, if samples (e.g. gamma rays, heat, formaldehyde, virucides, etc.) have been inactivated, andoperatedin a biosafety environment.

Control and Prevention

At present, 2 vaccines have been produced indifference to CCHFV. The first is a formalin-deactivated vaccine developed from a diseased breast-feeding mouse brain in Bulgaria. A DNA vaccine tried in mice is the second; neither vaccine has been subjected to official randomized clinical trials (Maltezou HC *et al*., 2010).Tick monitoring and exposure restriction to infected animals or humans are effective ways of defending against CCHFV. Protective clothing and application of repellent are recommended to reduce tick exposure. To avoid tick attachment, especially covering arms, legs and clothing should be chosen. Healthcare staff may be showing contaminated blood (or) tissue from CCHF patients in widespread areas. Such staff must also wear gloves, gowns, and face masks to minimize the risk of contamination; they must also follow sufficient measures for infection prevention to avoid occupational exposure. Moreover, CCHFV is prone to 1%hypochlorite and 2% glutaraldehyde and can killwithin 30 min by heating at 56°C. Illegal transport of animals between countries may subsidize the feast of CCHFV; preventing illegal transport of animals may decrease the cause of CCHFV (Ergonul O, 2008).

Conclusion

CCHF is a zoonotic disease and there are widespread tick vectors; various species might also be hosts. Individuals working with animals and health professionals who have contact with CCHF patients are at the highest risk of CCHFV infection. Monitoring of virus circulation in zoonotic focuses and training of risky groups are therefore important, these are currently the key infection control methods.

Acknowledgement

The authors wish the department of Industrial pharmacy of RIPER for encouraging the data collection.

Conflicts of Interests

Authors do not have any conflicts of interest with the publication of the manuscript

References

1. Whitehouse CA (2004). Crimean–Congo hemorrhagic fever. Antiviral research. 64(3):145-60.

2. Karti SS, Odabasi Z, Korten V, Yilmaz M, Sonmez M, Caylan R, Akdogan E, Eren N, Koksal I, Ovali E, Erickson BR (2004). Crimean-Congo hemorrhagic fever in Turkey. Emerging infectious diseases. 10(8):1379.

3. Nasirian H (2020). New aspects about Crimean-Congo hemorrhagic fever (CCHF) cases and associated fatality trends: A global systematic review and meta-analysis. Comparative Immunology, Microbiology and Infectious Diseases. 69:101429.

4. Papa A, Bożović B, Pavlidou V, Papadimitriou E, Pelemis M, Antoniadis A (2002). Genetic detection and isolation of Crimean-Congo hemorrhagic fever virus, Kosovo, Yugoslavia. Emerging infectious diseases. 8(8):852.
5. Estrada-Peña A, Jameson L, Medlock J, Vatansever Z, Tishkova F (2012). Unraveling the ecological complexities of tick-associated Crimean-Congo hemorrhagic fever virus transmission: a gap analysis for the western Palearctic. Vector-Borne and Zoonotic Diseases. 12(9):743-52.
6. Jahrling PB, Marty AM, Geisbert TW (2007). Viral hemorrhagic fevers. Medical Aspects of Biological Warfare, Office of the Surgeon General, United States Army, and Borden Institute, Walter Reed Army Medical Center, Washington, DC. 271-310.
7. Appannanavar SB, Mishra B (2011). An update on Crimean Congo hemorrhagic fever. Journal of global infectious diseases. 3(3):285.
8. Tanir G, Tuygun N, Balaban I, Doksöz O (2009). A case of Crimean-Congo hemorrhagic fever with pleural effusion. Jpn J Infect Dis. 62(1):70-2.
9. Günaydin N, Aydin K, Yilmaz G, Çaylan HR, Koksal I (2010). Crimean-Congo hemorrhagic fever cases in the eastern Black Sea Region of Turkey: demographic, geographic, climatic, and clinical characteristics. Turkish Journal of Medical Sciences. 40(6):829-34.
10. Tasdelen Fisgin N, Fisgin T, Tanyel E, Doganci L, Tulek N, Guler N, Duru F (2008). Crimean-Congo hemorrhagic fever: five patients with hemophagocytic syndrome. American journal of hematology. 83(1):73-6.
11. Yildirmak T, Tulek N, Bulut C (2016). Crimean–Congo haemorrhagic fever: transmission to visitors and healthcare workers. Infection. 44(5):687-9.
12. Halstead SB, Streit TG, Lafontant JG, Putvatana R, Russell K, Sun W, Kanesa-Thasan N, Hayes CG, Watts DM (2001). Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. The American journal of tropical medicine and hygiene. 65(3):180-3.
13. Tsai TF (1987). Hemorrhagic fever with renal syndrome: mode of transmission to humans. Laboratory animal science. 37(4):428.
14. Hoogstraal H (1979). The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia, Europe, and Africa. Journal of medical entomology. 15(4):307-417.
15. Bente DA, Forrester NL, Watts DM, McAuley AJ, Whitehouse CA, Bray M (2013). Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antiviral research. 100(1):159-89.
16. Izadi S, Naieni KH, Madjdzadeh SR, Nadim A (2004). Crimean-Congo hemorrhagic fever in Sistan and Baluchestan Province of Iran, a case-control study on epidemiological characteristics. International Journal of Infectious Diseases. 8(5):299-306.
17. Swanepoel R, Gill DE, Shepherd AJ, Leman PA, Mynhardt JH, Harvey S (1989). The clinical pathology of Crimean-Congo hemorrhagic fever. Reviews of infectious diseases. 11(Supplement_4): S794-800.
18. Mardani M, Jahromi MK, Naieni KH, Zeinali M (2003). The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran. Clinical infectious diseases. 36(12):1613-8.
19. Ozkurt Z, Kiki I, Erol S, Erdem F, Yılmaz N, Parlak M, Gundogdu M, Tasyaran MA (2006). Crimean–Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. Journal of Infection. 52(3):207-15.
20. Schwarz TF, Nsanze H, Longson M, Nitschko H, Gilch S, Shurie H, Ameen A, Zahir AR, Acharya UG, Jager G (1996). Polymerase chain reaction for diagnosis and identification of distinct variants of Crimean-Congo hemorrhagic fever virus in the United Arab Emirates. The American journal of tropical medicine and hygiene. 55(2):190-6.
21. Vanhomwegen J, Alves MJ, Zupanc TA, Bino S, Chinikar S, Karlberg H, Korukluoğlu G, Korva M, Mardani M, Mirazimi A, Mousavi M (2012). Diagnostic assays for Crimean-Congo hemorrhagic fever. Emerging infectious diseases.18(12):1958.

22. Maltezou HC, Andonova L, Andraghetti R, Bouloy M, Ergonul O, Jongejan F, Kalvatchev N, Nichol S, Niedrig M, Platonov A, Thomson G (2010). Crimean-Congo hemorrhagic fever in Europe: current situation calls for preparedness. Eurosurveillance.15(10):19504.
23. Ergonul O (2008). Treatment of Crimean-Congo hemorrhagic fever. Antiviral research. 78(1):125-31.